Clinical Trial Update: An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD [Phase 4]

View source ↗

Summary

Open-label Phase 4 trial of Macugen in subjects with neovascular age-related macular degeneration was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Sponsor: Pfizer | Conditions: Age Related Macular Degeneration (AMD), Macular Degeneration | Phase 4 | Status: TERMINATED | Results posted: 2010-12-17